554 related articles for article (PubMed ID: 21503910)
21. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
[TBL] [Abstract][Full Text] [Related]
22. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
Kaohsiung J Med Sci; 2017 Oct; 33(10):510-515. PubMed ID: 28962822
[TBL] [Abstract][Full Text] [Related]
23. Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Chayama K; Nakamura Y; Kumada H
Intervirology; 2012; 55(6):417-25. PubMed ID: 21325786
[TBL] [Abstract][Full Text] [Related]
24. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
25. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
[TBL] [Abstract][Full Text] [Related]
26. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
Ogurtsov PP; Kukhareva EI
Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
[TBL] [Abstract][Full Text] [Related]
27. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
Huang CF; Huang JF; Yang JF; Hsieh MY; Lin ZY; Chen SC; Wang LY; Juo SH; Chen KC; Chuang WL; Kuo HT; Dai CY; Yu ML
J Hepatol; 2012 Jan; 56(1):34-40. PubMed ID: 21703176
[TBL] [Abstract][Full Text] [Related]
28. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
[TBL] [Abstract][Full Text] [Related]
29. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
[TBL] [Abstract][Full Text] [Related]
30. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
[TBL] [Abstract][Full Text] [Related]
31. Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy.
Takita M; Hagiwara S; Arizumi T; Hayaishi S; Ueda T; Kitai S; Yada N; Inoue T; Minami Y; Chung H; Ueshima K; Sakurai T; Kudo M
Digestion; 2011; 84 Suppl 1():56-61. PubMed ID: 22156487
[TBL] [Abstract][Full Text] [Related]
32. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
33. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
[TBL] [Abstract][Full Text] [Related]
34. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
35. Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy.
Tahata Y; Hiramatsu N; Oze T; Urabe A; Morishita N; Yamada R; Yakushijin T; Hosui A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Yamada Y; Inada M; Katayama K; Tamura S; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2016 Oct; 88(10):1776-84. PubMed ID: 26991414
[TBL] [Abstract][Full Text] [Related]
36. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
37. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1.
Amanzada A; Schneider S; Moriconi F; Lindhorst A; Suermann T; van Thiel DH; Mihm S; Ramadori G
J Med Virol; 2012 Aug; 84(8):1208-16. PubMed ID: 22711348
[TBL] [Abstract][Full Text] [Related]
38. Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Miyazaki M; Iio S; Oshita M; Hagiwara H; Mita E; Inui Y; Hijioka T; Inada M; Tamura S; Yoshihara H; Inoue A; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2014 Apr; 49(4):737-47. PubMed ID: 23689988
[TBL] [Abstract][Full Text] [Related]
39. Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study.
Nishiguchi S; Enomoto H; Aizawa N; Nishikawa H; Osaki Y; Tsuda Y; Higuchi K; Okazaki K; Seki T; Kim SR; Hongo Y; Jyomura H; Nishida N; Kudo M
J Gastroenterol; 2014 Mar; 49(3):492-501. PubMed ID: 23543311
[TBL] [Abstract][Full Text] [Related]
40. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
